Phase 1 and 2 studies of crizotinib treatment have shown that the progression‐free survival (PFS) of patients with ALK‐positive NSCLC was 7–10 months, and the objective response rate (ORR) was approximately 60% 3, 11, 12. Here, ALK is linked to non-small cell lung carcinoma.